Effect of the synthetic endogenous opioid analog dalargin on the natural cytotoxicity of human lymphocytes
Aleksandrova EN, Nasonov EL, Vinogradov VA, Titov MI · 1988 · Biull Eksp Biol Med. 1988;105(4):442-445. PMID 3359025
This source appears in the Thymalin–Dalargin evidence review. A single-agent experiment, comparative study or patent alternative is not automatically a combined-treatment trial.
Reported findings and study design
Narrative findings; numerical extraction incomplete
Dalargin increased NK–target binding and the proportion of active NK cells in vitro. The abstract gives concentrations but no numerical cytotoxicity effect size.
Human peripheral-blood lymphocytes tested against K-562 target cells; donor and replicate counts unavailable.
Dose, route and schedule
Human lymphocytes preincubated with Dalargin 10⁻¹⁴–10⁻⁸ M; naloxone 10⁻⁶ M tested separately. Incubation duration and full dose–response table unavailable.
Protocol source ↗ · Original indexed abstract; historical research methods
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| NK-cell function | More effector–target contacts and active NK cells described | K-562 laboratory target assay; no clinical cancer outcome or numerical benefit estimate |
| Experimental exposure | Dalargin preincubation at 10⁻¹⁴–10⁻⁸ M | Duration unavailable; the later peak-range sentence has a malformed exponent and is not reconstructed |
| Naloxone finding | At 10⁻⁶ M, naloxone itself enhanced target contacts and lytic activity in this assay | Different response from the 1987 proliferation-blockade experiment; receptor effects are assay-dependent |
Findings apply to this preparation, assay and comparison. They do not establish Thymalin–Dalargin combination efficacy or a safe combined regimen.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Original response curves, donor counts and route-independent safety require full text.
- One activity-peak exponent is malformed in the indexed abstract; no corrected range is asserted.
- Natural cytotoxicity in vitro is not anticancer efficacy.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original indexed abstract
Review depth: Indexed abstract and citation checked; full original outcome tables not recovered
Source access and review scope
Original PubMed / Europe PMC indexed abstract checked. Missing group sizes, doses, raw outcomes and uncertainty are not reconstructed.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Original journal publication
Citation and original source
Original source: Aleksandrova EN, Nasonov EL, Vinogradov VA, Titov MI. Effect of the synthetic endogenous opioid analog dalargin on the natural cytotoxicity of human lymphocytes Biull Eksp Biol Med. 1988;105(4):442-445. PMID 3359025 1988.
Molekul research summary: https://molekul.io/research/dalargin-nk-cells-1988. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry